

Primary Mediastinal Large B-cell Lymphoma – A Case Report

Bruno Pelinson Fogaça Duarte¹ Amanda Scaff Mendes¹ Ana Clara Parizoti Rossini¹
José Carlos Medina Carvalho² Angelo Sementilli³

¹ School of Medicine, Universidade Metropolitana de Santos, Santos, SP, Brazil

² Department of Hematology and Laboratory Medicine, Universidade Metropolitana de Santos, Santos, SP, Brazil

³ Department of Pathology, Universidade Metropolitana de Santos, Santos, SP, Brazil

Address for correspondence Amanda Scaff Mendes, Faculdade de Medicina, Universidade Metropolitana de Santos, Santos, SP, Brazil (e-mail: amanda.scaff@hotmail.com; coordenacao.medicina@unimes.com.br).

Braz J Oncol 2024;20:s00441791656.

Abstract

Keywords

- ▶ lymphoma
- ▶ large B-cell
- ▶ diffuse
- ▶ superior vena cava syndrome
- ▶ neoplasms
- ▶ case reports

Primary mediastinal large B-cell lymphoma (PMBL) is an uncommon and aggressive subtype of non-Hodgkin large B-cell lymphoma that affects patients in the third and fourth decades of life. The objective of the present report is to describe the case of a male patient admitted to the emergency room with symptoms of dyspnea associated with signs of superior vena cava syndrome. The imaging exams revealed two masses in the mediastinum; the definitive diagnosis, established through an anatomopathological examination and immunohistochemistry, was of PMBL, and the patient was referred for chemotherapy.

Introduction

Primary mediastinal large B-cell lymphoma (PMBL) is an aggressive B-cell lymphoma that has a low prevalence in the population, occurring in 2.4% of non-Hodgkin lymphoma cases, accounting for approximately 3,000 cases in Brazil per year.¹ It is a subtype of diffuse large B-cell lymphoma (DLBCL) as it is immunophenotypically distinct, with more than 80% of cases showing CD30 expression, but it shares some clinical and biological characteristics with Hodgkin lymphoma of the nodular sclerosis subtype.^{1,2} This neoplasm usually affects young adults, predominantly women, and often presents as a bulky tumor in the anterior mediastinum, progressive in nature, with compressive symptoms, such as dyspnea, cough, dysphagia, and involvement of the upper airways or great vessels.¹

Due to its distinct clinicopathological characteristics, PMBL has been identified as a specific entity recognized by the World Health Organization (WHO) classification of lymphoid neoplasms,³ which is believed to originate from

thymic (medullary) B cells.⁴ Initially, the progression of the tumor tends to be localized, although in recurrence the disease can spread. Superior vena cava (SVC) obstruction is present in 25 to 30% of patients at the time of diagnosis while central nervous system (CNS) and bone marrow involvement are uncommon.^{2,4} The occurrence of superior vena cava syndrome (SVCS) is present in approximately 80% of cases of PMBL, due to the compression of adjacent structures by the mediastinal mass, with dyspnea as the most common symptom.⁵ The current paper aims to report a case of PMBL in a young male patient, highlighting the clinical presentation of this neoplasm, which has a low prevalence in the population, and the use of complementary methods for a proper diagnosis.

Case Report

A 24-year-old white male patient came to the emergency room with symptoms of dyspnea. A chest X-ray was

received
June 27, 2024
accepted
August 28, 2024

DOI <https://doi.org/10.1055/s-0044-1791656>
ISSN 2526-8732.

© 2024. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (<https://creativecommons.org/licenses/by/4.0/>).
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil



Fig. 1 Chest X-ray with evidence of mediastinal tumor masses.

requested, and two masses were seen in the mediastinum region (►**Fig. 1**). On admission for diagnosis of the mediastinal tumor mass associated with SVCS and thrombosis (►**Fig. 2**), a heterogeneous mass measuring 14.9×9.3 cm was detected on computed tomography (CT) in the anterosuperior mediastinum, with heterogeneous density, involving the thoracic aorta and compressing the SVC.

The biopsy of the mediastinal mass showed an anatomicopathological diagnosis of small cell proliferation with extensive necrotic areas (►**Fig. 3**). The immunohistochemical



Fig. 2 Patient with edema of limbs, chest, and cervical region due to thrombosis secondary to superior vena cava syndrome.




Fig. 3 (A) Proliferation of small lymphocytic cells and necrosis area (hematoxylin-eosin [HE]: 100x). (B) Proliferation of small lymphocytic cells (HE: 400x).

panel was positive for the AE1/AE3 markers, suggesting the thymic origin, and positive for CD3 in rare lymphocytes, CD20 diffusely (►**Fig. 4A**), and CD30 focally (►**Fig. 4B**) in atypical cells, suggesting the diagnosis of PMBL.

The positron emission tomography (PET) CT scan showed a lymph node cluster in the anterosuperior mediastinum (mediastinal bulky) measuring $17.2 \times 9.9 \times 15.4$ cm, in close contact with the ascending thoracic aorta and SVC, suggesting supra-diaphragmatic nodal lesions in the thoracic region with glycolytic hypermetabolism, compatible with an active lymphoproliferative neoplasm and slight anterior and posterior pericardial effusion, with no signs of tamponade. Computed tomography angiography of the chest showed evidence of opacity and consolidation in the middle lobe of the right lung, as well as a heterogeneous mass in the anterosuperior mediastinum measuring 14.9×9.3 cm, involving the thoracic aorta in the region of the aortic arch, compressing the SVC (►**Fig. 5**). The mass extended to the paratracheal and carinal regions, with a small pericardial and pleural effusion on the right, without mediastinal lymph node enlargement.

The treatment instituted was dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R), a combination of drugs indicated for the treatment of this disease: 6 cycles with an interval of 21 days each cycle.




Fig. 4 (A) Positive diffuse immunolabeling of CD20 in atypical cells (100x). (B) Positive focal immunolabeling of CD30 in atypical cells (100x).

Discussion

Symptoms related to compression or invasion of local structures are common, such as dyspnea and cough.¹ Half of the patients present signs and symptoms of SVCS, such as edema




Fig. 5 Chest angiotomography showing mediastinal masses involving the thoracic aorta and compressing the superior vena cava.

and pain in the upper limbs/neck; collateral venous patterning; breathing difficulties; malfunction in those with central venous catheters or arteriovenous access; or, rarely, extremity ischemia and the presentation of symptoms is relatively early, leading the patient to seek medical attention.⁶ This means that at the time of diagnosis, the majority of patients (around 80%) are in stage I or II of the disease. In this case, the patient had common symptoms of SVCS, which had not been previously diagnosed in the emergency department. The diagnosis of SVCS should be established through clinical history and physical examination, and it is important to pay attention to complaints that are typical of the condition.

The differential diagnosis of PMBL includes benign and malignant mediastinal tumors (which can cause external compression or direct invasion of the central venous system) and, less commonly, infectious and inflammatory entities that can present mediastinal involvement. Mediastinal tumors include DLBCL, with secondary mediastinal involvement, and the nodular sclerosis Hodgkin lymphoma.³ In addition, it is important to be aware of the non-malignant conditions that cause SVCS, which account for 15 to 40% of SVC obstructions in recent retrospective series. Most of these cases are related to the presence of indwelling intravascular devices. Other causes include stenosis due to pacemaker wires, intravascular hemodialysis catheters, long-term antibiotics, chemotherapy, or iatrogenic thrombus formation.⁷ Thus, the absence of an adjacent tumor directly invading or causing external compression of the SVC on imaging and having another confirmed diagnosis or the presence of an indwelling catheter is usually enough to make the distinction.

Corroborating the frequently reported origin in the thymus, the positive immunohistochemical expression of AE1/AE3 in the mediastinal mass establishes its thymic origin. Its locally invasive presentation in the anterior mediastinum was also observed on complementary imaging tests. A retrospective analysis of cases of PMBL showed that 93% of patients had an invasion of adjacent mediastinal structures. In approximately half of the patients, the primary tumor measures > 10 cm in its largest dimension and, therefore, constitutes a bulky disease.¹

The DA-EPOCH-R therapy used is corroborated by the guidelines of the European Society for Medical Oncology and other medical organizations as first-line therapy.² According to retrospective studies and single-arm clinical trials, excellent results have been obtained using the DA-EPOCH-R scheme, sparing patients the need for radiotherapy.⁸

The importance of early diagnosis of primary mediastinal large B-cell lymphoma, a neoplasm with a low prevalence, should be considered in the differential diagnosis in young patients with mediastinal manifestations, with a view to a precise therapeutic approach. The emphasis on clinical presentation, including compressive symptoms and SVCS, highlights the importance of early identification of these signs for effective management. In addition, the discussion on the specific immunophenotyping of PMBL and its WHO classification emphasizes its uniqueness among B-cell lymphomas.

Authors' Contributions

BPFD and ASM: Conception and design and writing of the manuscript; ACPR: Collection and assembly of data and writing of the manuscript; JCMC: Final approval of manuscript and provision of study materials or patient; and AS: Provision of study materials or patient.

Clinical Trials

None.

Funding

The authors declare that they did not receive funding from agencies in the public, private or non-profit sectors to conduct the present study.

Conflict of Interests

The authors have no conflict of interests to declare.

References

- 1 Savage KJ. Primary mediastinal large B-cell lymphoma. *Blood* 2022;140(09):955–970. Doi: 10.1182/blood.202008376
- 2 Cwynarski K, Marzolini MAV, Barrington SF, et al; British Society for Haematology Guidelines. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. *Br J Haematol* 2019;185(03):402–409. Doi: 10.1111/bjh.15731
- 3 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. *Leukemia* 2022;36(07):1720–1748. Doi: 10.1038/s41375-023-01962-5 PubMed
- 4 Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. *Br J Haematol* 2019;185(01):25–41. Doi: 10.1111/bjh.15778
- 5 Oliveira FAM, Santos ABVD, Brasil SAB. Linfoma Primário De Mediastino: Análise Retrospectiva Dos Fatores Prognósticos E Resposta À Terapia De Primeira Linha Nos Pacientes Da Santa Casa De São Paulo De 2008-2018. *Hematol Transfus Cell Ther* 2022;44:S123. Doi: 10.1016/j.htct.2022.09.207
- 6 Besteiro B, Teixeira C, Gullo I, Pereira S, Almeida M, Almeida J. Superior vena cava syndrome caused by mediastinal lymphoma: A rare clinical case. *Radiol Case Rep* 2021;16(04):929–933. Doi: 10.1016/j.radcr.2021.01.063
- 7 Seligson MT, Surowiec SM. Superior Vena Cava Syndrome. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441981/>
- 8 Zhou H, Xu-Monette ZY, Xiao L, et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. *Blood Cancer J* 2020;10(05):49. Doi: 10.1038/s41408-020-0312-7